IgA-nephropathy in children with alport syndrome

BACKGROUND. The widespread use of genetic methods in clinical practice has shown that pathogenic variants in COL4A3, COL4A4, COL4A5 genes associated with Alport syndrome (AS) are detected in 10 % of sporadic and in 20 % of familial cases of IgA nephropathy (IgAN), which suggested a relationship between the two diseases. THE AIM was to determine the frequency and characteristics of the course of IgAN in children with AS. PATIENTS AND METHODS. A single-centre retrospective pilot study included 102 patients with AS. The inclusion criteria were: age 2-18 years, genetic and/or morphological confirmation of AS, availability of morphological data of pts. The comparison group included children and adolescents 2-18 years with morphologically confirmed primary IgAN; the exclusion criterion was the presence of AS-specific glomerular basement membrane changes. IgAN was classified according to the MESTC scale. Demographic (gender, age), clinical (arterial hypertension, AH) and laboratory data (proteinuria (Pr, mg/m2/day), (Schwartz eGFR, ml/min/1.73m2) at the time of the biopsy and at the last examination of patients were assessed. Arterial pressure ≥95‰ for sex, age, height was defined as AH. Pr >100 mg/m2/day, Pr≥500 mg/m2/day and Pr>1000 mg/m2/day were defined as proteinuria, high-level proteinuria and nephrotic level proteinuria, respectively. The statistic parametric and nonparametric methods were used ("Statistica 10", StatSoft Russia). RESULTS. IgAN was detected in 3 of 102 children with AS (q=0.03): 2 girls had heterozygous variants in COL4A3 and COL4A4, a boy had X-linked AS. Two patients had nephrotic proteinuria, 1 had SRNS at onset of IgAN. The comparison group included 25 children with IgAN (17M). Baseline patients age (9±4.2 vs 13±2.7 years), frequency of AH (q1=0.66 vs q2=0.28), eGFR decrease (q1=0.33 vs q2=0.44), eGFR level (91±24 vs 90.8±24 ml/ min/1.73 m2), morphological characteristics of IgAN did not differ significantly by groups; patients with AS were more likely to have nephrotic proteinuria (q1=1 vs q2=0.32, p=0.023). At follow-up (3.8±1.4 years), the groups were comparable in age (12.3±5.2 vs 15±1.8 years), AH frequency (q1=0.66 vs q2=0.5), eGFR level (87±16 vs 91±13 ml/min/1.73m2); children with AS had higher grade Pr (800[0;1150] vs 30[10;100] mg/m2/day, p=0.048) and more often had high-level Pr (q1=0.66 vs q2=0.06, p=0.006) at follow-up observation. The AS was associated with the development of nephrotic-level Pr at onset (r=0.41, p=0.008) and with high-level Pr (r=0.38, p=0.012) during follow-up. CONCLUSION. IgAN was detected in 3 % of children with AS. The presence of COL4A3, COL4A4, COL4A5 genes variants is associated with more pronounced proteinuria at the onset of IgAN and its preservation in the follow-up, and may be a risk factor for more severe course glomerulonephritis. The main limitations of the study: small sample size and duration of follow-up.

1. Gast C, Pengelly RJ, Lyon M et al. Collagen (COL4A) mutations are the most frequent mutations underlying adult focal segmental glomerulosclerosis. Nephrol Dial Transplant 2016: 31: 961–970. doi: 10.1093/ndt/gfv32

2. Yao T, Udwan K, John R et al. Integration of genetic testing and pathology for the diagnosis of adults with FSGS. Clin J Am Soc Nephrol 2019; 14(2):213–223. doi: 10.2215/CJN.08750718

3. Trautmann A, Bodria M, Ozaltin F et al. Spectrum of steroidresistant and congenital nephrotic syndrome in children: the PodoNet registry cohort. Clin J Am Soc Nephrol 2015; 10(4): 592–600. doi: 10.2215/CJN.06260614

4. Savenkova ND, Chakhalian MI. Clinical-genetic features and therapy strategy of hereditary congenital and infantile nephrotic syndrome in children (literature review). Nephrology (Saint-Petersburg) 2019;23(5):17–28 (In Russ.). doi: 10.24884/1561-6274-2019-23-5-17-28

5. Groopman EE, Marasa M, Cameron-Christie S et al. Diagnostic Utility of Exome Sequencing for Kidney Disease. N Engl J Med 2019; 380(2):142–151. doi: 10.1056/NEJMoa1806891

6. Domingo-Gallego A, Pybus M, Bullich G et al.: Clinical utility of genetic testing in early-onset kidney disease: seven genes are the main players. Nephrol Dial Transplant 2021; Feb 3;gfab019. doi: 10.1093/ndt/gfab019

7. Li Y, Groopman EE, D'Agati V et al. Type IV Collagen mutations infFamilial IgA nephropathy. Kidney Int Rep 2020; 5(7):1075–1078. doi: 10.1016/j.ekir.2020.04.011

8. Stapleton CP, Kennedy C, Fennelly NK et al. An Exome sequencing study of 10 families with IgA nephropathy. Nephron 2020; 144:72–83. doi: 10.1159/000503564

9. Cambier A, Robert T, Hogan J et al. Rare collagenous heterozygote variants in children with IgA nephropathy. Kidney Int Rep 2021; 6(5):1326–1335. doi: 10.1016/j.ekir.2021.02.022

10. Barbour SJ, Coppo R, Zhang H et al. International IgA Nephropathy Network. Evaluating a new international risk-prediction tool in IgA nephropathy. JAMA Intern Med 2019; 179(7):942–952. doi: 10.1001/jamainternmed.2019.0600

11. Kwon CS, Daniele P, Forsythe A, Ngai C. A systematic literature review of the epidemiology, health-related quality of life impact, and economic burden of immunoglobulin A nephropathy. J Health Econ Outcomes Res 2021; 8(2):36–45. doi: 10.36469/001c.26129

12. Gibson J, Fieldhouse R, Chan MMY et al. Prevalence estimates of predicted pathogenic COL4A3-COL4A5 variants in a population sequencing database and their implications for Alport syndrome. J Am Soc Nephrol 2021; 32: 2273–2290. doi: 10.1681/ASN.2020071065

13. Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med 2013; 368:2402–2414. doi: 10.1056/NEJMra1206793

14. Waldherr R, Rambausek M, Duncker WD, Ritz E. Frequency of mesangial IgA deposits in a non-selected autopsy series. Nephrol Dial Transplant 1989; 4:943–946. doi: 10.1093/ndt/4.11.943

15. Masuda Y, Yamanaka N, Ishikawa A et al. Glomerular basement membrane injuries in IgA nephropathy evaluated by double immunostaining for α5(IV) and α2(IV) chains of type IV collagen and low-vacuum scanning electron microscopy. Clin Exp Nephrol 2015; 19(3):427–435. doi: 10.1007/s10157-014-1008-8

16. Lin X, Suh JH, Go G, Miner JH. Feasibility of repairing glomerular basement membrane defects in Alport syndrome. J Am Soc Nephrol 2014; 25(4):687–692. doi: 10.1681/ASN.2013070798

17. Lemley KV, Lafayette RA, Safai M et al. Podocytopenia and disease severity in IgA nephropathy. Kidney Int 2002; 61(4):1475– 1485. doi: 10.1046/j.1523-1755.2002.00269.x

18. Tsuji K, Suleiman H, Miner JH et al. Ultrastructural characterization of the glomerulopathy in Alport mice by helium ion scanning microscopy (HIM). Sci Rep 2017; 7:11696. doi: 10.1038/s41598-017-12064-5

19. Clark SD, Nabity MB, Cianciolo RE et al. X-Linked Alport dogs demonstrate mesangial filopodial invasion of the capillary tuft as an early event in glomerular damage. PLoS One 2016;11(12):e0168343. doi: 10.1371/journal.pone.0168343